SCHEMBL2597937

SCHEMBL2597937

Cc1ccc(C(=O)Nc2ccc(CC(=O)O)cc2C(=O)N(C)C)c(-c2ccc(C(F)(F)F)cc2)c1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PSEN1 P49768 1/20 0.48
PSEN2 P49810 1/20 0.48
APH1B Q8WW43 1/20 0.48
NCSTN Q92542 1/20 0.48
APH1A Q96BI3 1/20 0.48
PSENEN Q9NZ42 1/20 0.48
NR1H4 Q96RI1 2/20 0.45
PPARD Q03181 2/20 0.45
PPARG P37231 1/20 0.45
PPARA Q07869 1/20 0.45
MTTP P55157 6/20 0.43
RXRA P19793 3/20 0.39
RXRB P28702 3/20 0.39
RXRG P48443 3/20 0.39
PTGDR2 Q9Y5Y4 2/20 0.39
HDAC7 Q8WUI4 1/20 0.38
NTRK1 P04629 1/20 0.38
HSPH1 Q92598 1/20 0.38
PLK1 P53350 1/20 0.38
TBXA2R P21731 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2597850 0.89 PPARG (0.53) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL2597716 0.88 PSEN1 (0.46) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL2597714 0.84 MAPT (0.39) NR1H4PPARDPPARGPPARAMTTP
SCHEMBL3722420 0.83 MTTP (0.39) NR1H4PPARDPPARGPPARAMTTP
SCHEMBL2597977 0.83 NR1H4 (0.51) NR1H4PPARDPPARGPPARAMTTP
SCHEMBL3730905 0.82 MTTP (0.38) NR1H4PPARDPPARGPPARAMTTP
SCHEMBL14031718 0.81 MTTP (0.39) MTTPHDAC7NTRK1
SCHEMBL402457 0.80 MTTP (0.48) NR1H4PPARDPPARGPPARAMTTP
SCHEMBL13580512 0.80 MTTP (0.50) NR1H4PPARDPPARGPPARAMTTP
SCHEMBL400773 0.80 PPARA (0.55) NR1H4PPARDPPARGPPARAMTTP

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2571860-A1 2-PHENYL BENZOYLAMIDES Pfizer Inc (US) 2013-03-27 EP claimed
US-20130072519-A1 2-PHENYL BENZOYLAMIDES CONN EDWARD LEE (US) 2013-03-21 US claimed
WO-2011145022-A1 2-PHENYL BENZOYLAMIDES PFIZER INC. (US) 2011-11-24 WO claimed
EP-2571860-A1 2-PHENYL BENZOYLAMIDES Pfizer Inc (US) 2013-03-27 EP disclosed
US-20130072519-A1 2-PHENYL BENZOYLAMIDES CONN EDWARD LEE (US) 2013-03-21 US disclosed
WO-2011145022-A1 2-PHENYL BENZOYLAMIDES PFIZER INC. (US) 2011-11-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130072519-A1 2-PHENYL BENZOYLAMIDES APOB, MTTP, HADHB PSEN1 1469/4885PSEN2 1501/4885APH1B 386/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.